RECOVERY Trial
University of Oxford
  • Site Map
  • Accessibility
  • Cookies
  • Log in
  • Home
  • For patients
  • For Site Staff
  • Results
  • News
  • International
  1. Results
  2. Lopinavir-Ritonavir results

Lopinavir-Ritonavir results

press release

29 June 2020

Statement from the Chief Investigators: no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY

publications

5 October 2020

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial published in The Lancet


© 2021 Nuffield Department of Population Health
  • Freedom of Information
  • Privacy Policy
  • Copyright Statement
  • Site Map
  • Accessibility
  • Cookies
  • Log in
powered by Haiku
  • Welcome
  • For patients
    • Why is this research being done?
    • What is the purpose of this study?
    • Who is doing the study?
    • Who is being included in the study?
    • What happens next if I agree to be included in this study?
    • What are the possible benefits of being in the study?
    • What are the possible risks of being in the study?
    • Can I stop the study treatment or my participation early?
    • If I have any questions or problems, who can I call?
    • What information do you hold about me and how do you keep it private?
    • Do I have to take part?
    • Are there any financial costs or payments?
    • What else can you tell me?
    • What about my data privacy?
    • Videos
    • RECOVERY trial participant newsletter sign-up
    • RECOVERY trial participant newsletter opt-out
    • RECOVERY trial participant newsletter sign-up
    • RECOVERY trial participant newsletter opt-out
  • For Site Staff
    • For Site Staff
    • Pharmacy
    • Site Set-Up
      • RECOVERY Trial FAQs for sites
      • Site set-up
      • Data Monitoring Committee correspondence
      • Regulatory documents
    • Training
      • Training for site staff
      • Background and informed consent
      • 1st and 2nd randomisation
      • Children and neonates
      • Convalescent plasma and monoclonal antibodies
      • Follow-up
      • Oral Therapies
    • site teams
    • Follow-up data collection
    • Randomisation
    • Randomisation Training Confirmation
    • Background & Consent Training Confirmation
    • Children & Neonates Training Confirmation
    • Convalescent Plasma Training Confirmation
    • Monoclonal Antibodies Training Confirmation
    • Oral Therapies Training Confirmation
    • Follow-up Training Confirmation
    • Dimethyl Fumarate Training Confirmation
  • Results
    • Results
    • Dexamethasone results
    • Hydroxychloroquine results
    • Lopinavir-Ritonavir results
    • Study Protocol Archive
    • Azithromycin results
    • Convalescent Plasma results
    • Tocilizumab results
  • News
  • International
    • International sites
    • Indonesia
    • Nepal